GREB1

Overview

GREB1 (Growth Regulating Estrogen Receptor Binding 1) encodes an early estrogen-responsive gene product implicated in hormone-dependent cancer biology. In cancer genomics, GREB1 is notable as a fusion partner in a novel activating gene fusion identified in uterine leiomyosarcoma, a lineage in which hormone receptor fusions have therapeutic relevance.

Alterations observed in the corpus

  • GREB1-NR4A3 novel activating fusion identified in uterine leiomyosarcoma (ULMS) in the MET500 cohort of 500 metastatic solid tumors profiled by paired whole-exome and transcriptome sequencing PMID:28783718.

Cancer types (linked)

  • ULMS: GREB1-NR4A3 activating fusion identified as a novel event in uterine leiomyosarcoma PMID:28783718.

Co-occurrence and mutual exclusivity

  • No co-occurrence or mutual exclusivity data reported in the corpus to date.

Therapeutic relevance

  • The GREB1-NR4A3 fusion expands the targetable fusion landscape in uterine leiomyosarcoma; clinical actionability has not yet been demonstrated PMID:28783718.

Open questions

  • Whether GREB1-NR4A3 fusions represent a recurrent oncogenic event beyond the MET500 cohort, and whether kinase inhibitors applicable to NR4A3 fusions are active in ULMS, remain to be determined.

Sources

This page was processed by crosslinker on 2026-05-15.